These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 18637752)

  • 1. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
    Bartels DJ; Zhou Y; Zhang EZ; Marcial M; Byrn RA; Pfeiffer T; Tigges AM; Adiwijaya BS; Lin C; Kwong AD; Kieffer TL
    J Infect Dis; 2008 Sep; 198(6):800-7. PubMed ID: 18637752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.
    Susser S; Vermehren J; Forestier N; Welker MW; Grigorian N; Füller C; Perner D; Zeuzem S; Sarrazin C
    J Clin Virol; 2011 Dec; 52(4):321-7. PubMed ID: 21924672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.
    Susser S; Welsch C; Wang Y; Zettler M; Domingues FS; Karey U; Hughes E; Ralston R; Tong X; Herrmann E; Zeuzem S; Sarrazin C
    Hepatology; 2009 Dec; 50(6):1709-18. PubMed ID: 19787809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.
    Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C;
    Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
    Franco S; Bellido R; Aparicio E; Cañete N; García-Retortillo M; Solà R; Tural C; Clotet B; Paredes R; Martínez MA
    J Viral Hepat; 2011 Oct; 18(10):e578-82. PubMed ID: 21914079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.
    Tong X; Chase R; Skelton A; Chen T; Wright-Minogue J; Malcolm BA
    Antiviral Res; 2006 Jun; 70(2):28-38. PubMed ID: 16448708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.
    Suzuki F; Suzuki Y; Akuta N; Sezaki H; Yatsuji H; Arase Y; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Iwasaki S; Kumada H
    J Clin Virol; 2010 Jan; 47(1):76-8. PubMed ID: 19857995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
    Thomson JA; Perni RB
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir.
    Jiang M; Mani N; Lin C; Ardzinski A; Nelson M; Reagan D; Bartels D; Zhou Y; Nicolas O; Rao BG; Müh U; Hanzelka B; Tigges A; Rijnbrand R; Kieffer TL
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6236-45. PubMed ID: 24100495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.
    Trimoulet P; Belzunce C; Faure M; Wittkop L; Reigadas S; Dupon M; Ragnaud JM; Fleury H; Neau D
    HIV Med; 2011 Sep; 12(8):506-9. PubMed ID: 21410862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The resistance mutation R155K in the NS3/4A protease of hepatitis C virus also leads the virus to escape from HLA-A*68-restricted CD8 T cells.
    Salloum S; Kluge SF; Kim AY; Roggendorf M; Timm J
    Antiviral Res; 2010 Aug; 87(2):272-5. PubMed ID: 20488208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
    Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M
    J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells.
    Lin K; Kwong AD; Lin C
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4784-92. PubMed ID: 15561857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of HCV protease inhibitors.
    Chen KX; Njoroge FG
    Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors.
    Colson P; Purgus R; Borentain P; Gérolami R
    J Clin Virol; 2012 Feb; 53(2):178-80. PubMed ID: 22079973
    [No Abstract]   [Full Text] [Related]  

  • 18. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning.
    Cuypers L; Libin P; Schrooten Y; Theys K; Di Maio VC; Cento V; Lunar MM; Nevens F; Poljak M; Ceccherini-Silberstein F; Nowé A; Van Laethem K; Vandamme AM
    Infect Genet Evol; 2017 Sep; 53():15-23. PubMed ID: 28499845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates.
    Qi X; Bae A; Liu S; Yang H; Sun SC; Harris J; Delaney W; Miller M; Mo H
    Antiviral Res; 2009 Feb; 81(2):166-73. PubMed ID: 19063924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.